Horst Sievert 教授：专心致志、脚踏实地，永远将患者放在首位

So I think the way of communication is a very open one in both conferences CSI Frankfurt as well as in China above Hangzhou. There's always an open discussion and the focus is really on learning on how to do procedures, how to make procedures more safe，how to avoid complications. We also cover topics like latest clinical trials and that kind of thing, but the focus is really on how to do it and the focus in both conferences, our conferences, CSI and Frankfurt.  And China about Hangzhou is a live case demonstrations step by step. How to do things right？I think these are the highlights of both of our conferences.

两国在学术氛围方面非常类似，都秉持这一种开放交流的学术态度。无论是在CSI大会上，还是CHINA VALVE (HANG ZHOU)，我们术者主要关注的是实操手术，一方面是基于学习和交流，另一方面主要是考虑和讨论手术的安全性，以及如何来避免并发症的问题。当然，会上我们也会交流一些临床研究等等，但最重要的还是实操环节。这也就是为什么CSI和CHINA VALVE (HANG ZHOU)大会上，我们都会有手术直播以及手把手教学的环节，这是两国专家在交流方面共同关注的内容。

 I still remember that when the first meeting started in 2015, it mainly talked about the technology of TAVR...And then now the field is expanding and  other valves are covered, mitral valve is covered, tricuspid valve, pulmonary  valves. So it's really a huge development. In the beginning only two or three different valves, now there are many different devices available also the embolic protection devices and other accessory devices have been introduced to the field. So there is a huge progress.

我记得2015年第一次会议开始的时候，主要是围绕TAVR这一项技术开展的。现在，随着整个领域的不断拓展，会上围绕结构瓣领域，还开展了二尖瓣、三尖瓣、和肺动脉瓣的学术交流，这在技术上是一个非常大的飞跃。而且当时在TAVR瓣膜选择上页只有2-3个器械，现在甚至还有脑保护装置或者其他的植入装置，这些变化都是非常巨大的。

So I historically in the past, when I think back 15 years, 20 years, the Chinese companies were kind of making copycats. But then very soon, actually your engineers are so bright that you have developed devices which are partially ahead of the European-US devices. It's really a major progress in engineering and designing.

回顾历史，或是在15-20年前，确实有很多的公司包括一些工程师，会效仿国外的瓣膜设计。但现在，中国工程师们也研发了很多先进的瓣膜，这些技术都已经超越了欧洲，在工程或者是在瓣膜的设计上也已经非常领先了。

I think it's a great platform. China Valve involved international faculty to a right extent. Are you covering everything which is coming up in the field. You have a very good interaction at the conference. You are presenting online, so the format is perfect.

我认为这是个很好的平台，因为它有邀请国外的一些讲者在会议上分析、分享最先进的临床和诊疗技术，而且是线上线下结合的模式，是一个完美的平台。

This is really, I have said pretty often this is the next big wave in In cardiology. I wish you think back we started with peripheral interventions PCI, and then we added structural and valvular interventions. And the next big wave in that regard will be heart failure interventions.

Whether it is the intervention therapy of the valve, the intervention therapy of the heart failure or the ventricular reconstruction, electrical stimulus and other technologies, I can't tell you which one is the best.But that is something where China should become involved more than in the past.

我认为经导管介入的心衰治疗会是整个领域当中下一步的浪潮，因为在整体发展阶段当中，我们先是经历了PCI然后是结构性的介入治疗。我觉得下一波的浪潮就会是心衰的介入治疗，无论是瓣膜的介入治疗、心衰的介入治疗还是心室重构、电刺激等技术，我无法告诉你哪一个是最好的，但是我觉得中国在这方面需要更多的参与。

I mean in all different fields of structural interventions, there is a lot of progress to expect within the next couple of years. If you ask me what is the general trend, I think one important aspect is to leave less behind. Now we are working on technologies to close select at the bench without leaving anything behind. This will be an important aspect in general for structural interventions in the future.

在结构性的心脏病介入治疗中有很多不同的发展方向，从大趋势来说，我认为在治疗之后留下的植入物越少越好。现在我们正在研究这项技术，是一个英文的概念“Leave Less Bbehind”，就是治疗之后，在体内留下的这些植入物越少越好，这对于将来的结构介入治疗，是一个重要的体现。

Obviously, less regulatory is much better. All the attempts to add more safety for the patients by regulatory things actually failed. And this is another advantage in China that there is money which can be invested, whereas in Europe and in us this becomes more and more difficult.

对我来说一个相对宽松的监管环境会更好，政策审批的环境如果能够更优化，更简单也更好。鼓励该领域当中资本的投入和流动，是中国的另一大优势，现在在中国有很多的资本愿意投资到医疗器械、医疗技术中，但这种现象在欧洲和美国越来越少见。

Artificial intelligence will become extremely important in many aspects. One of the aspects we have been involved is telemedicine, for example, artificial intelligence plays a key role in analyzing the massive data of remote medical care. Imaging is the next big field for artificial Intelligence, and The third field is operations and interventions. Also, this can be learned by machine learning and performed by computers and robotics.

我认为人工智能在未来会有更多的使用，而且会显得越来越重要。例如人工智能在分析远程医疗大量的数据上起到了关键的作用。此外，未来第二个较大的人工智能可以发挥作用的领域就是影像学。第三，我认为在未来的手术也可以由机器人来完成，相信在欧洲和中国都有很多机器人手术有关的讨论。

I will certainly be at the opening ceremony. I will give a talk about the future of the device interventions for heart failure. I think this will be the main topic of my talk.

开幕式当天我会在现场，而且会围绕介入中心衰治疗的前沿发展进行主题演讲，这也是我比较关注的一个话题。

At first I would like to congratulate Jian’an wang and his team to make this happen 10 years of continuous success. Congratulations，that is a big achievement. And if the China above congress is growing as it has grown in the past，probably in 10 years he will have 1 million attendees. So congratulation a big success for the future.

首先，在此衷心祝贺王建安教授和他的团队在过去十年间，将中国瓣膜会从一个小会成功发展成一个规模巨大的会议。相信在未来10年，中国瓣膜领域能够持续发展，可能10年之后，CHINA VALVE (HANG ZHOU)的参会人数能够达到一百万人次。

I think when you work in medicine, you have to take care of patients. You can be successful in medicine only when your interest is taking care of patients that should be your major focus. Not the other things you don't, If you want to become famous，then it's better to become a football player this will be much more on influence on the internet. But in medicine is really you to have an interest in taking care of patients.

我认为当你在医学界工作的时候，你必须把照顾病人放置于首位。只有当你的兴趣或重心是照顾病人时，你才能在医学上取得进步，这应该是你的主要关注点。如果你想出名，或许你可以去成为一名足球运动员，这将在互联网上有更大的影响力。但是在医学领域，以患者为中心才是最重要的。